Dr. Arab is Assistant Professor of Medicine at the Pontificia Universidad Catolica de Chile School of Medicine. Trained at the Pontificia Universidad Catolica, Chile and Mayo Clinic, Rochester, MN, USA. Dr. Arab is a Gastroenterology and Hepatology specialist, Transplant Hepatologist and Physician Scientist with interest in translational and clinical research in alcohol-related liver disease and non-alcoholic fatty liver disease. He is the Director for Living Donor Liver Transplantation at his institution. He has published more than 100 peer-reviewed papers on gastrointestinal and liver diseases in high-impact factor journals, co-authored several book chapters and delivered lectures on liver-related topics at national and international meetings. Additionally, he is spearheading an international collaboration group that aims to study alcohol-related liver disease and non-alcoholic fatty liver disease. Dr. Arab is a member of the American Association for the study of Liver Diseases (AASLD), European Association for the Study of the Liver (EASL), and Latin-American Association for the Study of the Liver (ALEH). He is currently the Secretary of the Special Interest Group on alcohol-related liver disease of the AASLD and Vice-Chairs its global outreach subcommittee. Additionally, he is the Vice-President of the Chilean Hepatology Association and member of the Education & Scholarship Committee of the International Liver Transplantation Society (ILTS).
Department of Gastroenterology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
Ilaria Barchetta, MD, PhD, has received the MD Degree from Sapienza University of Rome in 2007 and the PhD in Clinical and Experimental Hepatology in 2011. She is a Board Certified Specialist in Internal Medicine at the Sapienza University from 2016. She has focused her PhD and 5-year post-doc studies working on diabetes and clinical correlates of ectopic fat distribution, adipose tissue inflammation and non-alcoholic fatty liver disease. Her studies at Sapienza University were integrated with a post-doc period spent at the Lund University, Sweden, funded by an award from the Italian Diabetes Society, working on the role of proneurotensin, an intestinal peptide promoting gut fat absorption, in determining metabolic diseases and NAFLD/NASH. As a clinical researcher, she is involved in study design, data collection, advanced statistics (degree in Biostatistics, Sapienza University), data interpretation and scientific writing. For her research achievements, she has been awarded several honors and competitive funding; among all, in 2016 she was awarded a National Research Grant from Eli Lilly Foundation for carrying out a 3-year research project on diabetes and bone health.
She has recently received the National Scientific Qualification (ASN) by the Italian Ministry of University and Research as Associate Professor in Endocrinology.
Department of Experimental Medicine, Sapienza University, Rome, Italy.
Dr. Bril has always had a strong interest in clinical research and biostatistics, embarking early-on on a career as a physician-scientist. After completing internal medicine residency at Instituto Universitario CEMIC, Buenos Aires, Argentina, he joined the Division of Endocrinology, Diabetes and Metabolism at the University of Florida in Gainesville, Florida, USA, in 2012 as a Post-Doctoral Associate. Later, Dr. Bril stayed as a faculty member until 2020, when he moved to University of Alabama at Birmingham, Birmingham, AL, USA.
Dr. Bril’s main research interest has been to understand the metabolic mechanisms that promote the progression from isolated steatosis to NASH and advanced fibrosis. He has also focused on identifying diagnostic biomarkers and pharmacological approaches that could help us change the natural history of this disease. His research combines the use of stable isotopes to assess nutrient turnover, as well as novel imaging techniques to characterize the severity of liver disease.
His work has resulted in significant peer-reviewed articles in the field, including two randomized controlled trials on the use of pioglitazone in patients with NASH. He has also reported on how the presence of NAFLD and/or NASH influences changes in dyslipidemia, diabetes control, and insulin resistance, all mechanisms potentially leading to increased cardiovascular risk in patients with NAFLD. Dr. Bril has also focused on the assessment of potential new plasma and imaging biomarkers for the diagnosis of NAFLD and NASH. He serves as reviewer, and participates in the editorial board, of important journals in the field of diabetes and liver disease.
Division of Endocrinology, Diabetes and Metabolism, University of Alabama at Birmingham, Birmingham, AL, USA.
Bachelor in Biochemistry and Ph.D. in Cellular and Molecular Biology from the Pontificia Universidad Católica de Chile and prosecuting studies to obtain the MD degree. His first field of research was related to the mechanism of fibrosis induction through inflammatory processes in the setting of dystrophic muscular diseases. Where he developed strategies to treat these genetic disorders by using a pharmacocellular approach. These results are now under clinical studies and are part of a patent application (USPTO). After his Ph.D. training, he received funding from "Fundacion COPEC" and the award for innovation from the same entity. His doctoral training was also supervised by Dr. James Tidball (University of California Los Angeles (UCLA), studying the molecular mechanism by which NFkB modulates profibrogenic factors in the muscle and how fibrosis affects muscle strength. In this context, he moved his research to the understanding of chronic pathologies where muscle mass wasting plays a crucial role. Thus, He began to study Sarcopenia associated with Liver diseases. In order to receive specific training in liver diseases, he did a postdoctorate supervised by Dr. Ariel Feldstein (University of California San Diego (UCSD) and Dr. Marco Arrese (Pontificia Universidad Catolica de Chile) in the field of innate immunity in Fatty Liver Diseases. In this postgraduate training, he studied the role of the inflammasome and Kupffer cells. Now he is working in pharmacological mechanisms designed to specifically modulates Kupffer cell activation in the setting of Fatty Liver Disease and trying to decipher the underlying mechanisms of liver-related sarcopenia. He is also: (1) Principal Investigator of FONDECYT 1211879 (Deciphering muscle-liver connections in MAFLD: experimental and clinical studies), (2) Associate researcher in ongoing projects (Fondecyt 1161646,1191145, 1191183, 1200227), (3) Assistant Professor of at Universidad Bernardo O'Higgins (Chile). He has published more than 40 manuscripts in top international journals, and supervised 1 Ph.D. dissertations, 4 Master's projects, and seven undergraduate theses. He has been invited lecturer in international academic, scientific, and Medical organizations.
Department of Gastroenterology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile;
School of Medicine, Faculty of Medical Sciences, Universidad Bernardo O´Higgins, Santiago, Chile.
Rocío Gallego-Durán currently holds a post-doctoral position in the Institute of Biomedicine of Seville (IBiS), in the SeLiver Group led by Prof. Romero-Gómez. She graduated from the University of Seville with a Bachelor´s degree in Biology, and in 2017 she completed her PhD in Molecular Biology and Clinical Research, Cum Laude with the International Mention, and she further obtained the Doctoral Extraordinary Award from the University of Seville in 2019.
Rocío has a longstanding research interest in the development of non-invasive biomarkers for non-alcoholic fatty liver disease (NAFLD) diagnosis, as well as new therapeutic strategies with potential to be transferred to the bedside mainly based on epigenetic approaches. This is evidenced by the (co)-authorship of 36 peer-reviewed original papers and reviews, 12 in first decile and 9 in first quartile. Rocío became a principal investigator of two competitive-funded projects, one funded by Consejería de Salud de la Junta Andalucía and the most recent by Instituto de Salud Carlos III, all regarding novel biomarker discovery and therapies for NAFLD in both human and preclinical models. Besides, she is co-investigator in 11 national and international competitive-funded projects. =
Outside of a laboratory setting, Rocío is an active member of several scientific associations and networks (AEEH, EASL, AASLD, CIBEREHD), and has been invited speaker in different scientific conferences, as well as reviewer for a total of 8 peer-reviewed journals.
UCM Digestive Diseases and SeLiver Group, Virgen del Rocío University Hospital, Institute of Biomedicine of Seville, University of Seville, Seville, Spain.
Biomedical Research Networking Center in Hepatic and Digestive Diseases (CIBEREHD), Seville, Spain.
Research Interests: non-invasive biomarkers; epigenetics; NAFLD
His current position is Assistent Professor in Internal Medicine. In his clinical practice, he mainly manages patients with liver disease. His translational and clinical research activity deals with non-alcoholic steatohepatitis, alcohol use disorder, viral hepatitis, cirrhosis, liver transplant.
He attended many conferences and courses in hepatology and he achieved the title of Transplant Hepatologist by AISF (Italian Association for the Study of Liver). He is actually involved in many clinical and experimental studies on liver disease.
Division of Internal Medicine, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Research Interests: liver transplant; cirrhosis; viral hepatitis; NASH; alcohol use disorder; metabolic disorders
A reliable academic and researcher with a strong track record of achievements and professional and research experiences focus on diverse field of biomedical sciences, including drug development, molecular and cellular biology and translational research.
He received his PhD in Physiology in 2012 followed by a postdoctoral fellowship at the faculty of Pharmacy, Granada University (Spain), and a visiting academic position at the School of Healthcare Science, Manchester Metropolitan University (UK). He joined the Charité University Medicine-Berlin for 2 years as a fellow of Alexander Von Humboldt foundation and joined Helmholtz Center Munich in 2018. He has more than 160 publications and won many prestigious fellowship awards.
Molecular Physiology, Faculty of Science, Beni-Suef University, Beni Suef, Egypt.
Research Interests: cardiovascular diabetology; diabetes and obesity; oxidative stress/inflammation signaling pathways; nuclear receptors; drug development and nanomedicine; drug-induced toxicity
From 2018, she is a Post-Doc Fellow at the Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico in Milan. Previously, she was a Post Graduate Associate and a Post Graduate Fellow in 2014 and 2012 respectively, at the Liver Center, in the Department of Internal Medicine (Yale University, USA). In these periods, she has acquired a good knowledge of molecular and biochemical techniques for the generation of cellular and animal models of non-alcoholic fatty liver disease (NAFLD).
She has dedicated myself to the study of genetic and environmental factors predisposing to the development of metabolic liver diseases and in particular to NAFLD and its more advanced forms, among which hepatocellular carcinoma (HCC). Her research activity is focused on the understanding of the molecular mechanisms underlying metabolic liver diseases, insulin resistance and diabetes, paying attention to genetics and environmental factors (obesity, insulin resistance) predisposing to of NAFLD and HCC, to the development of cellular genetic models of NAFLD through genomic editing techniques, such as CRISPR/Cas9 and to the role of macro and micronutrients and their interaction with inherited factors in NAFLD onset.
General Medicine and Metabolic Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy.
Research Interests: NAFLD; NASH; HCC; genetics; preclinical models of NAFLD; CrispR/Cas9
Dr. Mohammed's primary research focuses on treating microvascular obstruction using a novel ultrasound-targeted microbubble cavitation technique. He is also studying the effect of ultrasound treatment on the molecular mechanism and structural and functional parameters of cardiovascular complications. He is also actively involved in evaluating a novel vascular scaffold for focal delivery of antiplatelet therapy in a rabbit model to avoid complications associated with an antiplatelet agent following percutaneous coronary interventions. In addition, he is also developing in vitro and in vivo cardiovascular and cancer disease models to evaluate the efficacy of drug-loaded microbubbles and nanodroplets.
Center for Ultrasound Molecular Imaging and Therapeutics , School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
His current position is physician-in-charge in the Division of Internal Medicine and Metabolism at the Civil Hospital of Modena, University of Modena and Reggio Emilia, Italy. In his clinical practice, he manages patients with primary and secondary dyslipidemias, metabolic syndrome, metabolic liver diseases and inherited lysosomal storage disorders. His research activity mainly deals with hepatic metabolic disorders, lipid disorders and lysosome inborn errors of metabolism.
He is member of AISF (Italian Association for the Study of the Liver), EASL (European Association for the Study of the Liver), SIMI (Italian Association of Internal Medicine), and SISA (Italian Society for the Study of Atherosclerosis). He attended many conferences and courses in hepatology and metabolism. He is actively involved in several clinical and experimental studies on familial hypercholesterolemia, Gaucher disease and non-alcoholic steatohepatitis.
Division of Internal Medicine and Metabolism, Department of Internal Medicine, University Hospital of Modena, Modena, Italy.
Research Interests: inborn errors of metabolism; inherited lysosomal storage disorders; dyslipidemias; atherosclerosis; diabetes mellitus; obesity; metabolic syndrome; chronic liver diseases
Dr Raluca Pais is MD PhD in Hepatogastroenterology Department and Institute of Cardiometabolism and Nutrition, Pitié-Salpêtrière Hospital, Paris, France. She first completed her medical training at University of Medicine and Pharmacy “Iuliu Hatieganu” Cluj Napoca, Romania. She earned her doctoral degree at the University Pierre et Marie Curie, Paris VI for her work on the natural history and progression of non-alcoholic fatty liver disease, liver and cardiovascular related comorbidities related to NAFLD. She serves as regular reviewers for journals like Liver International, Clinics and Research in Hepatology and Gastroenterology, Journal of Hepatology, Alimentary Pharmacology and Therapeutics, Hepatology.
She participated in phase II and III clinical trials in NAFLD. She is member of scientific societies: EASL (European Association for the Study of Liver Disease), AASLD and AFEF (Association Francaise pour l’Etude du Foie). She is part of the EU project Horizon 2020 EPOS (Elucidating Pathways of Steatohepatitis) and IMI2 project LITMUS. Together with the Pr V Ratziu, she founded and is responsible of NAFLD-Liver Clinic at Pitié-Salpêtirère Hospital, Paris, France.
Institute of Cardiometabolism and Nutrition, Hepatogastroenterology Department, Pitié-Salpêtrière Hospital, Sorbonne University, INSERM, Paris, France.
Research Interests: NAFLD; NASH; chronic liver disease; obesity; metabolic syndrome; diabetes; bariatric surgery
Medical doctor, specialist in Cardiovascular Diseases, he is currently working as a cardiologist and researcher at the Cardiac Rehabilitation Unit, "Villa Delle Magnolie" Rehabilitation Clinic, Castel Morrone (Caserta), Italy. Since September 2019 he is Young Italian Ambassador of European Association of Preventive Cardiology (EAPC), whereas since 2020 he is Board member of the Italian Society for Cardiovascular Prevention (SIPREC) Young Group. Currently, his main field of interest is cardiovascular prevention and rehabilitation. His interest is to investigate the field of cardiac rehabilitation with echocardiography and other advanced techniques. Indeed, his other field of interest is advanced echocardiography, also applied to patients with heart failure and chronic ischemic heart disease. Specifically, he performed a period of in-depth study of cardiac imaging techniques (transthoracic and transesophageal echocardiography, cardiac CT and cardiac MRI) at the Cardiac Imaging Unit, “La Paz” University Hospital (Madrid, Spain), head Dr. Yangüela Mar Moreno and specialization thesis in cardioncology, tutor dr. Teresa López Fernández.
Cardiac Rehabilitation Unit, Villa delle Magnolie Clinic Rehabilitation, Castel Morrone, Caserta, Italy.
Her professional background is focused on translational research in the field of NAFLD, with proven experience in the development of in vitro systems (from monocultures to more complex co-culture systems), in vivo models, and the translation to human subjects. For the last eleven years, she has been leading a multidisciplinary research team constituted by master’s and Ph.D. students, post-docs, and medical doctors. Her current scientific interests can be summarized as 1) the molecular mechanisms underlying the pathogenesis of the liver disease, 2) the extrahepatic components involved in the onset of NAFLD, 3) the study of bioactive properties of natural compounds as a therapeutic approach, and 4) the in silico individuation and in vivo validation of non-invasive biomarkers for the early diagnosis of liver fibrosis
Liver Research Center, Italian Liver Foundation, Trieste, Italy.
Research Interests: NAFLD; NASH; obesity; noninvasive biomarkers; preclinical models
Dr. Daniele Santi graduated with Honors from the Medical School of the University of Modena and Reggio Emilia, Italy in 2008. He obtained with Honors the specialization in Endocrinology and Metabolism in 2014 and his PhD in Clinical and Experimental Medicine in 2017 from the University of Modena and Reggio Emilia. Currently, Dr. Santi works as Assistant Professor at the Unit of Endocrinology of the Department of Biomedical, Metabolic and Neural Sciences of the University of Modena and Reggio Emilia, Italy. He has published a large number of scientific manuscripts in peer-reviewed journals, in the field of Endocrinology, Andrology and Reproductive medicine. He obtained the ESE young investigator awards in 2015. Dr. Santi is a member of the editorial boards or reviewer in high impact scientific journals and an active member of scientific committees and societies.
Unit of Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Research Interests: reproductive; osteoporosis; cardiovascular risk; spermatogenesis; bone metabolism; hormonal analysis; andrology
She is a translational physician with specific training in metabolism and nutrition. Her research interest focuses on regulation of lipid metabolism and metabolic diseases and more specifically, on understanding the heterogeneity of non-alcoholic fatty liver disease (NAFLD). During her training in UK, she investigated the effects of omega-3 fatty acid treatment on NAFLD and studied the effects of synbiotic [Bifidobacterium animalis (subsp. lactis BB-12) plus fructo-oligosaccharide] on meta-organismal pathways responsible for dyslipidemia, intestinal permeability, nutrient absorption, NAFLD, gut hormones production and metabolic inflammation. Her work led to two first-author publications demonstrating that DHA+EPA treatment successfully drives tissue DHA enrichment and reduces liver fat percentage (Scorletti et. al. Hepatology 2014). In addition, she showed that there exists a gene-treatment interaction. Specifically, the 148MM genotype of PNPLA3 is associated with a decreased response to DHA+EPA treatment (Scorletti et. al. J Hepatology 2015). In her postdoctoral training, she will continue to build on my previous experience in metabolic and liver disease by developing new basic science skills that will allow me to investigate the effects of a recently discovered Perilpin 2 (PLIN2) polymorphism on hepatocellular lipid droplet biology and sphingolipid metabolism.
Department of Gastroenterology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.
Research Interests: lipid metabolism; insulin resistance; metabolic diseases; NAFLD; gut microbiota dysbiosis